Physician profile
Henry D Clarke
NPI 1609851310
$1,942,581.95
in general payments reported to CMS, 2019-2025
6 companies · $456K in 2025
The $456K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208K · 2020: $133K · 2021: $168K · 2022: $322K · 2023: $262K · 2024: $393K · 2025: $456K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.0M · Consulting Fee: $89K · Travel and Lodging: $7,534 · Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,012,393.84 |
| Consulting Fee | $89,259.33 |
| Travel and Lodging | $7,534.32 |
| Food and Beverage | $2,019.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $1,412,580.73 | 2019-2025 | Rosa |
| Conformis, INC. | $465,810.74 | 2019-2022 | |
| Restor3d, INC. | $63,254.22 | 2023-2025 | |
| Stryker Corporation | $745.37 | 2021-2025 | Mako |
| Uoc USA INC | $171.41 | 2023 | U2 Press-Fit and Psi |
| Molnlycke Health Care US, LLC | $19.48 | 2024 | Mepilex Border Post-Op Ag, Avance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.